Publications by authors named "R THORNTON"
Network hypersynchrony is emerging as an important system-level mechanism underlying seizures, as well as cognitive and behavioural impairments, in children with structural brain abnormalities. We investigated patterns of single neuron action potential behaviour in 206 neurons recorded from tubers, transmantle tails of tubers and normal looking cortex in 3 children with tuberous sclerosis. The patterns of neuronal firing on a neuron-by-neuron (autocorrelation) basis did not reveal any differences as a function of anatomy.
View Article and Find Full Text PDFObjectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.
Methods: Immunocompetent adults who had received two doses of BNT162b2 and any licensed COVID-19 booster at least three months prior were eligible.
Article Synopsis
- - The study aims to assess the effectiveness and cost-efficiency of low-dose amitriptyline as a second-line treatment for patients with irritable bowel syndrome (IBS) in primary care, especially when first-line treatments fail.
- - Conducted as a pragmatic, double-blind, placebo-controlled trial across 55 general practices in England, the design included both quantitative outcomes and qualitative experiences from participants and general practitioners regarding the treatment.
- - Participants included adults over 18 diagnosed with IBS who did not respond to initial therapies; they received either amitriptyline or a placebo for 6 months, with a focus on measuring the difference in IBS symptoms to see if the medication has a significant impact.
Objectives: PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. We report data for second boosters among individuals 50-<70 years old primed with AZD1222 (50-<70y-AZD1222) until Day 84.
Methods: Immunocompetent adults who received any first booster ≥three months prior were eligible.
Background: Irritable bowel syndrome (IBS) can cause troublesome symptoms impacting patients' quality of life and incur considerable health service resource use. Guidelines suggest low-dose amitriptyline for IBS as second line treatment, but this is rarely prescribed in primary care.
Aim: To explore patients' and general practitioners' (GPs) views and experiences of using low-dose amitriptyline for IBS.